Radiofrequenzablation bei tumoren des urogenitaltrakts (nierenzellkarzinom, prostatakarzinom, leiomyome des uterus) [Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)]
Warmuth M, Fischer S

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' objectives
Radiofrequency ablation (RFA) is a relatively new, minimally-invasive ablation method that destroys tumors by local application of heat. This systematic review evaluates the following indications of RFA for the treatment of benign and malignant tumors of the urogenital tract: renal cell carcinoma, prostate cancer and uterine leiomyoma.

Authors' conclusions
According to GRADE, the quality of evidence is very low due to the uncontrolled study design of the included case series and the inadequate control group of the included RCT (HIFU) of RFA for the treatment of uterine leiomyomas. Overall, the available evidence is insufficient to assess the efficacy and safety of RFA compared to surgical resection for the treatment of urogenital tumors. Currently, the inclusion into the hospital benefit catalogue is not recommended.

Final publication URL
http://eprints.hta.lbg.ac.at/963/1/DSD_59.pdf

Indexing Status
Subject indexing assigned by CRD

MeSH
Catheter Ablation; Tomography, X-Ray Computed; Prostatic Neoplasms; Uterine Neoplasms; Kidney Neoplasms

Language Published
German

Country of organisation
Austria

English summary
An English language summary is available.

Address for correspondence
Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 Email: stefan.fischer@hta.lbg.ac.at

AccessionNumber
32012000777

Date abstract record published